New research shows it’s possible to edit the DNA of human embryos with more precision. But scientists warn it’s still not ...

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool originally discovered as a bacterial defence mechanism. Scientists have repurposed it ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

Gene therapy represents one of medicine’s most ambitious attempts to treat disease at its root cause by altering the genetic code itself. The approach works by recovering the functions of critical ...

"Traditional gene-editing technologies work best with single mutations and are expensive to optimize, so gene therapies tend to focus on the mutations that are the most common," Buffington said. "But ...

Cardiovascular diseases could be among the world’s first medical conditions to be treated by changing a patient’s genes. If ongoing phase 3 trials succeed, gene editing will offer a novel therapy for ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine. Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike ...

Sickle-cell disease and β-thalassemia are inherited blood disorders that are caused by mutations in the HBB gene (encoding a component of adult hemoglobin) and are characterized by severe, lifelong ...

Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...

Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.

Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...

ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...